We studied a group of workers from one of the aircraft factories in Moscow. All of them were given a diagnosis of metabolic syndrome. We detected the abnormalities in lipidic and carbohydrate metabolisms, essential hypertension, abdominal obesity, and changes in hemostasis and fibrinolysis systems, as well as anomalies in some biochemical blood values. The patients were given the therapy of eicozyme-10 with eikonole, coenzyme Q10 and vitamin E for two months. Many values of the studied organism systems improved as a result of the medical treatment as well as the general state of patients.

For 2 months, 33 patients with the metabolic syndrome (MS) took a biologically active food additive as bifeinol, detovit, squalenol, which contained vitamins, minerals, essential amino acids, dietary cellulose, and a complex of polysaturated fatty acids. This yielded a positive result as decreases in body weight by 8%, in the levels of cholesterol, triglycerides, and low-density lipoproteins by 8.3, 27.8, and 9.3%, respectively. The food additive is recommended for the planned course use in patients with MS.

35 patients with diabetes mellitus type 2 complicated with hyperlipidemia, coronary heart disease were treated during 8 months with poseidonol--polyunsaturated fatty acid family omega 3 (PUFA--omega 3). It was shown that hypercoagulation and hypofibrinolysis in these patients occurred. Treatment with poceidonol increased plasminogen activator activity and decreased coagulation and reduced atherogenic index.

35 patients with diabetes mellitus type 2 complicated with hyperlipidemia, coronary heart disease, were treated for 8 months with poseidonol which incorporates essential polyunsaturated fatty acids and fat-soluble vitamins. Poseidonol reduced atherogenic index from 4.2 to 3.15. The study of blood coagulation and fibrinolysis points to signs of hypocoagulation and normalization of fibrinolytic activity against previous hypercoagulation and fibrinolysis depression.

33 patients with ischemic heart diseases, hyperlipidemia and blood hypercoagulation took tycveinol which consists of polyunsaturated fatty acids in a dose of 2.0 g twice a day for 2 months. A positive result manifested by a 14% drop in cholesterol, 29.7% in triglycerides, 21% in beta-lipoproteins. Alpha-lipoproteins rose by 26%, atherogenic index reduced from 3.24 to 1.89. Hypercoagulatory tension relieved due to normalization of euglobulin lysis, higher activity of plasminogen tissue activator, slow blood clotting. Side effects on hepatic or renal function, mineral metabolism were not observed.

Thirty five patients with type 2 diabetes mellitus complicated by cardiovascular diseases received 6-month treatment for hyperlipidemia with poseidonol that represents a set of essential polyunsaturated fatty acids. This yielded good results as 11.6%-, 30%- and 24.2% decreases in the levels of cholesterol, triglycerides, and beta-lipoprotein, respectively, and a 9.9%- increase in alpha-lipoprotein. Lipid metabolism became normal in 34.2% of the patients, the remaining had positive changes as normalization of 1 to 3 lipid parameters. The tolerance of the agent was good, no negative effect on hepatic and renal functions was found.

An antilipidemic effect of poseidonol was tested in 123 patients with ischemic heart disease, stable angina of effort (II-III functional class), 40 patients with secondary pyelonephritis and 40 patients with chronic hepatosis-hepatitis associated with chronic alcoholism or diabetes mellitus. The patients had also hyperlipidemia. A positive effect of poseidonol was established: cholesterol content fell by 25.4, 20.6 and 18.7%, respectively; triglycerides level decreased by 63, 42 and 21.4%, respectively; B-lipoproteins fell by 55.5, 36.9 and 13.1%, respectively. High density lipoproteins rose by 40.2, 27 and 69.9%, respectively. No adverse effects either on the liver or kidney functions were observed.

Proteolytical preparation moricrasa was isolated from hepatopancreas of Paralithodes camtshatic. Moricrasa and its fractions were used for lysis of cicatricial tissue under in vitro conditions. It was found that moricrasa in concentrations 0,5 mg/ml and 2 mg/ml lysed the cicatrix during 72 and 14-16 hours, respectively. The fraction consisted of collagenolytic proteinase PC and trypsin releated maximal activity of fraction of moricrasa was absent.

Proteolytical preparation moricrasa was isolated from hepatopancreas of Paralithodes camtshatic. Moricrasa and its fractions were used for lysis of cicatricial tissue under in vitro conditions. It was found that moricrasa in concentrations 0.5 mg/ml and 2 mg/ml lysed the cicatrix during 72 and 14-16 hours, respectively. The fraction consisted of collagenolytic proteinase PC and trypsin revealed maximal activity of fraction of moricrasa was absent.

Forty patients with coronary heart disease (CHD) concurrent with hyperlipidemia were divided into 2 groups according to the baseline fibrinolytic activity. The group with the depressed fibrinolytic system displayed the highest atherogenicity index and levels of cholesterol, low and very low density lipoprotein cholesterol and half levels of high density lipoproteins. After 45-day ingestion of docanol, a new Russian food additive containing docosahexanoic and eicosapentaenoic acids there were positive changes in the lipid spectrum in the both groups. The fibrinolytic changes were heterodirectional: activator and plasma activities increased in the group of fibrinolytic depression while in the group of baseline normal fibrinolysis the activity of plasminogen activator fell.

Fibrinolytic and thrombolytic properties of morikrase, a complex of proteinases obtained from hepatopancreatic tissues of king crab (Paralithodes camtschatica), were studied in vivo and in vitro. High fibrinolytic activity and dose-dependent activating properties were detected on standard and heated fibrin plates. The preparation maintained its properties during long-term storage at 4 degrees and 22 degrees C. The thrombolytic activity of the drug, affecting the preformed thrombus, was observed both in vitro and in vivo, in rats with experimental thrombosis. Two-phase alteration of the fibrinolytic system and moderate hypocoagulation were found after intravenous administration of morikrase.

An ointment containing, 1% morikrase (a complex of proteinases isolated from hepatopancreatic tissues of king crab Paralithodes camtschatica) exhibited the wound healing properties and did not irritate the skin tissues during long-term treatments of rats. Only slight hypocoagulation was observed in intact animals after external application of the ointment. At the same time, the drug caused an increase in fibrinolytic activity in blood of rats with purulent wounds due to activation of the plasminogen activator.